PRTG_OUT_1 [2025-04-28 11:24:53 -0400] 6201 Bytes | 1739 tokens | Cum: 1739 tkns (21.74% of 8k)
==========================================================================

We need a winner today and it's already 11:24 AM on Mon Apr 28, 2025 ... So let's find out if Portage Biotech (PRTG) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at $10.74 up from $8.45. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Portage Biotech (PRTG)
IPO: IPO date unknown
Market Cap: $13,591,409
Shares Outstanding: 1,120,000
Exchange: XNAS
Description: Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Here’s a list of headlines for Portage Biotech:

Today 06:00AM - Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Mar-27-25 04:15PM - Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Mar-12-25 08:00AM - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Feb-12-25 04:15PM - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Jan-30-25 04:30PM - Portage Biotech Announces Completion of $2.15 Million Private Financing
Jan-06-25 05:00AM - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
Dec-17-24 07:00AM - Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
Dec-12-24 04:15PM - Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
Nov-26-24 04:05PM - Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
Aug-27-24 08:00AM - Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
Aug-15-24 07:00AM - Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update
Aug-13-24 07:00AM - Portage Biotech Announces 1-for-20 Reverse Stock Split
Aug-12-24 07:30AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Apr-15-24 07:05AM - Immuno-oncology company Portage Biotech to evaluate strategic alternatives
Apr-12-24 10:33AM - Portage Biotech previews possible closure as it halts programs, hunts for strategic options
Apr-12-24 10:33AM 08:01AM - Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
Mar-26-24 08:01AM - Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Feb-28-24 05:10PM - Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Jan-04-24 08:00AM - Portage Biotech Reports Business and Strategic Update
Nov-28-23 04:01PM - Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
Nov-06-23 08:01AM - Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
Sep-29-23 08:00AM - Portage Biotech Announces $6.0 Million Registered Direct Offering

Prior AI Reports for PRTG:
1. 2025-04-17 – Score: 65 – Target: 12.6000 – Highs: 8.8799 / 9.8000 / 15.82
portage-biotech-rocketing-stock-amidst-financial-turbulence
2. 2025-03-27 – Score: 55 – Target: 7.2600 – Highs: 4.7583 / 13.2000 / 9.89
small-cap-company-shows-potential-despite-mixed-performance-indicators
3. 2025-03-24 – Score: 30 – Target: 4.9500 – Highs: 4.8000 / 4.4616 / 4.69
portage-biotech-high-insider-ownership-amid-negative-market-trends

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-28T10:00:00Z - Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
B2 - 2025-03-12T12:00:00Z - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
B3 - 2025-01-06T10:00:00Z - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
B4 - 2024-07-22T09:24:37Z - Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket - Benzinga
B5 - 2024-04-17T17:36:19Z - Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B6 - 2024-04-12T12:01:00Z - Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Portage Biotech (PRTG).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

PRTG_OUT_3 [2025-04-28 11:24:54 -0400] 965 Bytes | 252 tokens | Cum: 1993 tkns (24.91% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/28/3068995/0/en/Portage-Biotech-Reports-Confirmatory-Preclinical-Results-in-Mesothelioma-Supporting-First-In-Human-Trial-of-PORT-7.htmlPortage Biotech reports positive preclinical data for its selective adenosine A2B receptor inhibitor PORT-7 in a murine mesothelioma model, demonstrating superior single-agent activity compared to anti-PD1 antibody and further improvement in combination. The company plans to commence a first-in-human clinical trial with PORT-7.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRTG_OUT_5 [2025-04-28 11:24:55 -0400] 988 Bytes | 286 tokens | Cum: 2281 tkns (28.51% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T14:40:52Z - Portage Up 22% On Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of PORT-7...
A2 - 2025-04-28T13:32:05Z - Portage Biotech stock soars on promising preclinical results By Investing.com...
A3 - 2025-04-28T13:32:05Z - Portage Biotech stock soars on promising preclinical results By Investing.com...
A4 - 2025-04-28T12:12:57Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Autonomix Medical (NASDAQ:AMIX), Abpro...
A5 - 2025-04-28T11:35:08Z - Portage Biotech (PRTG) Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PRTG_OUT_7 [2025-04-28 11:24:56 -0400] 1181 Bytes | 341 tokens | Cum: 2624 tkns (32.80% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Portage Up 22% On Preclinical Results In Mesothelioma Supporting First-In-Human Trial Of PORT-7**Date: 2025-04-28Source: {'uri': 'rttnews.com', 'dataType': 'news', 'title': 'RTTNews'}URL: https://www.rttnews.com/3532261/portage-up-22-on-preclinical-results-in-mesothelioma-supporting-first-in-human-trial-of-port-7.aspxShares of Portage Biotech Inc. (PRTG) gained over 22% on Monday morning after the clinical-stage immuno-oncology company reported confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.

PRTG is currently trading at $10.38, up $1.93 or 22.84%, on the Nasdaq. The stock opened its trading at $8.45 after closing Friday at $11.31. The stock has traded between $2.10 and $23.01 in the past 52-week period.

The new data in a murine mesothelioma model demonstrated single agent activity for PORT-7 that was superior to treatment wi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRTG_OUT_9 [2025-04-28 11:24:57 -0400] 974 Bytes | 220 tokens | Cum: 2846 tkns (35.58% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): th single agent anti-PD1 antibody.

Moreover, the combination of PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone.

Immunohistochemistry of the tumors revealed the formation of tertiary lymphoid structures in the mice receiving the combination. This indication of a favorable immune response was accompanied by increases in immune effector cells in mice treated with the combination.

Mesothelioma is an aggressive cancer with limited treatment options in need of novel approaches to overcome immune resistance. Portage is making preparations to commence a first-in-human clinical trial with PORT-7.

For comments and feedback contact: [email protected]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRTG_OUT_11 [2025-04-28 11:24:57 -0400] 238 Bytes | 59 tokens | Cum: 2907 tkns (36.34% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRTG_OUT_13 [2025-04-28 11:24:58 -0400] 251 Bytes | 78 tokens | Cum: 2988 tkns (37.35% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

PRTG_OUT_15 [2025-04-28 11:25:07 -0400] 4892 Bytes | 1193 tokens | Cum: 4184 tkns (52.30% of 8k)
==========================================================================

This is our set of metrics for Portage Biotech.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+----------------------+
| Volume: 7,436,659 | Perf Month: 129.51% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 1.22M | Perf Quarter: 163.02% | Short Float: 82.41% | ROE: -194.84% |
+-------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 20.99 | Index: - | Short Ratio: 0.11 | ROI: -4812.45% |
+-------------------+-----------------------+------------------------+----------------------+
| RSI (14): 65.15 | Market Cap: 12.11M | Short Interest: 0.13M | Sales Surprise: - |
+-------------------+-----------------------+------------------------+----------------------+
| ATR (14): 1.96 | Shs Outstand: 1.12M | Beta: 0.90 | EPS Surprise: - |
+-------------------+-----------------------+------------------------+----------------------+
| SMA20: 41.39% | Shs Float: 0.16M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+------------------------+----------------------+
| SMA50: 87.06% | Inst Own: 6.94% | Sales past 5Y: 0.00% | Earnings: Nov 26 AMC |
+-------------------+-----------------------+------------------------+----------------------+
| SMA200: 115.62% | Insider Own: 75.46% | Employees: 7 | |
+-------------------+-----------------------+------------------------+----------------------+
| Perf Week: 18.92% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+-------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by Portage Biotech officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 10.63
Average Volume: 2448651.35
30-Day High: 10.63
30-Day Low: 4.9
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Portage Biotech (PRTG).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Portage Biotech.

2) MARKET_SCORE[]
This conversation was initiated because PRTG is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for PRTG.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, PRTG could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect PRTG to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Portage Biotech.

11) ETHICAL_RATING[]
Rate Portage Biotech’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Portage Biotech.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

PRTG_IN_17 [2025-04-28 11:25:07 -0400] 126 Bytes | 29 tokens | Cum: 4447 tkns (55.59% of 8k)
==========================================================================

====================================
[2025-04-28 11:25:07] # Analysis Completed
Elapsed Time: 18.39 seconds